Why Is JANUX THERAPEUTICS I (JANX) Stock Down Today?

Janux Therapeutics shares fell 22.75% to close at $13.62 on Monday. The sharp decline followed the release of initial Phase 1 data for JANX011, which analysts described as overdone relative to market expectations.

What Happened

Janux Therapeutics announced positive initial Phase 1 data for JANX011 in healthy volunteers, supporting planned development in patients with autoimmune disease. The company stated the results provide clinical validation for its ARM platform. Despite the positive framing, the stock sold off heavily. William Blair characterized the reaction to the Phase 1 data as overdone. Truist Securities maintained a Buy rating on the stock and raised its price target to $27. Barclays and Wedbush also updated their price targets for Janux Therapeutics.

What The Data Shows

The stock opened at $17.76, a 0.8% gap from the prior close of $17.63. It reached a session high of $18.25 at 8:35 AM ET before dropping to a session low of $12.43 at 9:45 AM ET. Volume so far stands at 2.7 million shares, which is 3.2 times the 3-month daily average. The company has a market cap of $1.1 billion and is unprofitable with a trailing twelve-month EPS of -1.59. Revenue grew 132.9% over the trailing twelve months, but the net margin is -428.7%. The stock has a beta of 2.39 and a 52-week range of $12.12 to $35.34. The stock printed 13 fresh 52-week lows on November 9, 2026.

What To Watch

Investors will monitor coverage breadth and further analyst reactions to the Phase 1 data. The scheduled earnings date was not provided in the available facts.